---
name: aria-comparison
description: >
  Multi-country regulatory comparison skill for FDA, EU MDR, and MFDS.
  Compares regulatory requirements across target regions and identifies key differences.
  Use for strategic multi-market planning and harmonization analysis.
allowed-tools: Read Grep Glob
user-invocable: false
metadata:
  version: "1.0.1"
  category: "domain"
  status: "active"
  updated: "2026-02-11"
  modularized: "false"
  tags: "comparison, multi-country, FDA, EU-MDR, MFDS, regulatory-analysis"
  knowledge-base-date: "2026-01"

# MoAI Extension: Progressive Disclosure
progressive_disclosure:
  enabled: true
  level1_tokens: 100
  level2_tokens: 2500

# MoAI Extension: Triggers
triggers:
  keywords: ["comparison", "compare", "multi-country", "regulatory difference", "harmonization"]
  phases: ["run"]
---

# Multi-Country Regulatory Comparison Skill

## Quick Reference

**Purpose**: Compare regulatory requirements across FDA (US), EU MDR (Europe), and MFDS (Korea) for specific regulatory topics or requirement areas.

**Input**: Regulatory topic or requirement area, target countries
**Output**: Side-by-side comparison matrix, key differences, harmonized standards, strategic recommendations
**Knowledge Base Date**: 2026-01

---

## Decision Framework

### Common Comparison Topics

#### Clinical Evidence Requirements
- **FDA**: Clinical data requirements per 21 CFR 860, IDE regulations for investigational devices
- **EU MDR**: Clinical evaluation per Annex XIV, clinical investigation per Article 62
- **MFDS**: ì„ìƒì‹œí—˜ ê³„íš ìŠ¹ì¸ (Clinical Trial Plan Approval), ì„ìƒì  ì„±ëŠ¥ì‹œí—˜ (Clinical Performance Testing)

#### Quality System Requirements
- **FDA**: 21 CFR Part 820 (Quality System Regulation)
- **EU MDR**: ISO 13485 + EU MDR Annex IX (QMS certification)
- **MFDS**: ì˜ë£Œê¸°ê¸° ì œì¡° ë° í’ˆì§ˆê´€ë¦¬ ê¸°ì¤€ (GMP for medical devices)

#### Post-Market Surveillance
- **FDA**: MDR (Medical Device Reporting), Post-approval studies
- **EU MDR**: PMCF (Post-Market Clinical Follow-up), PMS (Post-Market Surveillance)
- **MFDS**: ì‹œíŒ í›„ ì¡°ì‚¬ (Post-Market Surveillance), ë¶€ì‘ìš© ë³´ê³  (Adverse Event Reporting)

#### Labeling and IFU Requirements
- **FDA**: 21 CFR Part 801 (Labeling requirements)
- **EU MDR**: Annex I Section 23 (Information supplied by manufacturer)
- **MFDS**: ì˜ë£Œê¸°ê¸° í‘œì‹œÂ·ê¸°ì¬ ë“±ì— ê´€í•œ ê·œì •

#### Technical Documentation
- **FDA**: Design history file, Device master record
- **EU MDR**: Technical documentation per Annex II/III
- **MFDS**: ê¸°ìˆ ë¬¸ì„œ (Technical File) per ì˜ë£Œê¸°ê¸°ë²• ì‹œí–‰ê·œì¹™

#### Risk Management
- **FDA**: Risk analysis per FDA Guidance on risk management
- **EU MDR**: ISO 14971 compliance (harmonized standard)
- **MFDS**: ISO 14971 compliance + ìœ„í•´ì„± í‰ê°€ (Risk Assessment)

---

## Workflow

### Step 1: Load Prior Context (Optional)

Check for prior pipeline data:
- Classification results (`.aria/products/<product-name>/<date>/classification.summary.md`)
- Pathway selection (`.aria/products/<product-name>/<date>/pathway.summary.md`)
- Use prior context to inform comparison focus areas

If NO prior context: Proceed with user-specified comparison topic

### Step 2: Identify Comparison Topic

User provides either:
- Specific regulatory topic (e.g., "clinical evidence requirements", "post-market surveillance")
- Requirement area (e.g., "labeling", "quality system")
- Product-specific comparison (when prior context available)

Extract target countries from user input (default: FDA, EU MDR, MFDS)

### Step 3: Apply Comparison Framework

For each target country and topic:

**Comparison Dimensions**:
1. **Regulatory Basis**: Specific regulation/standard referenced
2. **Key Requirements**: Core mandatory elements
3. **Submission Timing**: When documentation is required (pre-market, post-market)
4. **Verification Method**: How compliance is verified (self-declaration, third-party audit, regulatory review)
5. **Penalties for Non-Compliance**: Enforcement consequences

**Comparison Matrix Structure**:

| Dimension | FDA | EU MDR | MFDS |
|-----------|-----|--------|------|
| Regulatory Basis | [Citation] | [Citation] | [Citation] |
| Key Requirements | [List] | [List] | [List] |
| Submission Timing | [When] | [When] | [When] |
| Verification | [Method] | [Method] | [Method] |

### Step 4: Identify Similarities and Differences

**Harmonized Areas** (similarities across regions):
- ISO 13485 (Quality Management)
- ISO 14971 (Risk Management)
- IEC 60601 series (Electrical safety for medical devices)
- IEC 62304 (Medical device software)
- IEC 62366 (Usability engineering)

**Key Differences**:
- Clinical evidence depth (EU MDR most stringent, FDA varies by class, MFDS moderate)
- Notified Body role (EU only)
- Post-market surveillance intensity (EU MDR PMCF most extensive)
- Language requirements (Korea requires Korean labeling)

### Step 5: Strategic Recommendations

Based on comparison results:

**Multi-Market Strategy Options**:
1. **Harmonized Approach**: Design documentation to meet the most stringent requirement (usually EU MDR), reducing regional adaptation
2. **Sequential Submission**: Target easiest market first (often FDA 510(k) or MFDS Grade 1-2), build precedent for other markets
3. **Parallel Submission**: Simultaneous multi-region submission when resources permit

**Cost-Benefit Analysis**:
- Harmonization upfront cost vs. later adaptation cost
- Translation and localization budget (especially for Korea)
- Notified Body fees (EU only)
- Clinical data reuse potential across regions

### Step 6: Assign Traffic Light

- **ğŸŸ¢ GREEN**: Requirements substantially aligned across regions, minimal adaptation needed
- **ğŸŸ¡ YELLOW**: Significant differences exist, expert consultation recommended for harmonization strategy
- **ğŸ”´ RED**: Conflicting requirements detected, fundamental approach change needed per region

### Step 7: Generate Output

Output structure (Korean language):

```markdown
# ë‹¤êµ­ê°€ ê·œì œ ë¹„êµ ë¶„ì„ ê²°ê³¼

## ë¹„êµ ì£¼ì œ
- **ì£¼ì œ**: [Comparison Topic]
- **ëŒ€ìƒ êµ­ê°€**: FDA (ë¯¸êµ­), EU MDR (ìœ ëŸ½), MFDS (í•œêµ­)
- **ë¶„ì„ ì¼ì**: [YYYY-MM-DD]

## ë¹„êµ ë§¤íŠ¸ë¦­ìŠ¤

### [Topic Area 1]

| í•­ëª© | FDA | EU MDR | MFDS |
|------|-----|--------|------|
| ê·œì œ ê·¼ê±° | [FDA Citation] | [EU Citation] | [MFDS Citation] |
| í•µì‹¬ ìš”êµ¬ì‚¬í•­ | - [Req 1]<br>- [Req 2] | - [Req 1]<br>- [Req 2] | - [Req 1]<br>- [Req 2] |
| ì œì¶œ ì‹œì  | [Timing] | [Timing] | [Timing] |
| ê²€ì¦ ë°©ë²• | [Method] | [Method] | [Method] |

**ë°ì´í„° ì¶œì²˜**: FDA [Citation], EU MDR [Citation], MFDS [Citation]

### [Topic Area 2]
[...ë™ì¼í•œ êµ¬ì¡° ë°˜ë³µ...]

## ê³µí†µ í‘œì¤€ (Harmonized Standards)
- **ISO 13485**: ì˜ë£Œê¸°ê¸° í’ˆì§ˆê²½ì˜ì‹œìŠ¤í…œ (FDA, EU, MFDS ëª¨ë‘ ì¸ì •)
- **ISO 14971**: ì˜ë£Œê¸°ê¸° ìœ„í•´ì„± ê´€ë¦¬ (ê³µí†µ ì ìš©)
- **IEC 60601 ì‹œë¦¬ì¦ˆ**: ì „ê¸° ì˜ë£Œê¸°ê¸° ì•ˆì „ì„± (ê³µí†µ í‘œì¤€)

## ì£¼ìš” ì°¨ì´ì 
1. **ì„ìƒ ë°ì´í„° ìš”êµ¬ ìˆ˜ì¤€**:
   - EU MDR: ê°€ì¥ ì—„ê²© (Class IIa ì´ìƒ ëŒ€ë¶€ë¶„ ì„ìƒ ë°ì´í„° ìš”êµ¬)
   - FDA: ë“±ê¸‰ë³„ ì°¨ë“± (Class IIIëŠ” PMA ì„ìƒ í•„ìˆ˜, Class IIëŠ” 510(k) ì‹¤ì§ˆì  ë™ë“±ì„±)
   - MFDS: ì¤‘ê°„ ìˆ˜ì¤€ (Grade 3-4 ì„ìƒ/ë¹„ì„ìƒ ë°ì´í„°)

2. **ì¸ì¦ ê¸°ê´€ ì—­í• **:
   - EU MDR: Notified Body í•„ìˆ˜ (Class IIa ì´ìƒ)
   - FDA: í•´ë‹¹ ì—†ìŒ (FDA ì§ì ‘ ì‹¬ì‚¬)
   - MFDS: í•´ë‹¹ ì—†ìŒ (MFDS ì§ì ‘ ì‹¬ì‚¬)

3. **ì‚¬í›„ ê´€ë¦¬ ê°•ë„**:
   - EU MDR: PMCF ê³„íš ë° ë³´ê³ ì„œ í•„ìˆ˜
   - FDA: MDR ë³´ê³  + PAS (Post-Approval Study, Class III)
   - MFDS: ì‹œíŒ í›„ ì¡°ì‚¬ + ì¬ì‹¬ì‚¬ (ì¼ë¶€ í’ˆëª©)

## ì „ëµ ê¶Œì¥ì‚¬í•­
- **ì ‘ê·¼ ë°©ì‹**: [Harmonized / Sequential / Parallel]
- **ê·¼ê±°**: [Rationale in Korean]
- **ìš°ì„  ì‹œì¥**: [Recommended first market]
- **ì¡°í™” ê°€ëŠ¥ì„±**: [Harmonization opportunities]

## ìœ„í—˜ë„ í‰ê°€
- **Traffic Light**: [ğŸŸ¢ GREEN / ğŸŸ¡ YELLOW / ğŸ”´ RED]
- **í‰ê°€**: [Risk assessment]

[If YELLOW or RED]: **âš ï¸ ì „ë¬¸ê°€ ê²€í†  ê¶Œì¥**: ê·œì œ ìš”êµ¬ì‚¬í•­ ì°¨ì´ê°€ í¬ë¯€ë¡œ ë‹¤êµ­ê°€ ì „ëµ ìˆ˜ë¦½ ì‹œ ê·œì œ ì „ë¬¸ê°€ ìƒë‹´ì„ ê¶Œì¥í•©ë‹ˆë‹¤.

## ë‹¤ìŒ ë‹¨ê³„ ì œì•ˆ
1. ê°€ì¥ ì—„ê²©í•œ ìš”êµ¬ì‚¬í•­(ë³´í†µ EU MDR) ê¸°ì¤€ìœ¼ë¡œ ë¬¸ì„œ ì‘ì„± ê³ ë ¤
2. ë²ˆì—­/í˜„ì§€í™” ì˜ˆì‚° ê³„íš (íŠ¹íˆ í•œêµ­ ë¼ë²¨ë§)
3. ê·œì œ ì „ë¬¸ê°€ì™€ ë‹¤êµ­ê°€ ì „ëµ ê²€í† 

## ë©´ì±… ì¡°í•­
âš ï¸ **ë³¸ ìë£ŒëŠ” ì°¸ê³  ì •ë³´ì´ë©°, ê·œì œ ìë¬¸ì´ ì•„ë‹™ë‹ˆë‹¤.** ê°êµ­ ê·œì œëŠ” ì§€ì†ì ìœ¼ë¡œ ì—…ë°ì´íŠ¸ë˜ë¯€ë¡œ, ì‹¤ì œ ì œì¶œ ì „ ìµœì‹  ê·œì œ ìš”êµ¬ì‚¬í•­ì„ í™•ì¸í•˜ì‹œê³  ê·œì œ ì „ë¬¸ê°€ì™€ ìƒë‹´í•˜ì‹œê¸° ë°”ëë‹ˆë‹¤.

---
**ìƒì„± ì¼ì‹œ**: [Timestamp]
**ARIA Plugin Version**: 2.0.0
```

### Step 8: Generate Context Simplifier Summary

Create `.summary.md` file for downstream pipeline:

```markdown
# Comparison Summary

**Topic**: [Comparison Topic]
**Date**: [YYYY-MM-DD]

- **Decision**: Multi-country comparison completed
- **Countries**: FDA, EU MDR, MFDS
- **Traffic Light**: [GREEN/YELLOW/RED]
- **Key Differences**: [Top 3 differences in bullet points]
- **Harmonized Standards**: ISO 13485, ISO 14971, IEC 60601
- **Recommended Strategy**: [Harmonized/Sequential/Parallel]
- **Escalation**: [Yes/No with reason if yes]
- **Sources**: FDA regulations, EU MDR text, MFDS ì˜ë£Œê¸°ê¸°ë²•

---
This summary is consumed by `/aria:brief` command.
```

---

## Data Source Strategy

1. **Built-in Knowledge** (Primary): Embedded regulatory comparison frameworks for FDA, EU MDR, MFDS
2. **Prior Pipeline Data** (Input): `.summary.md` files from classification/pathway steps (optional)
3. **External Tools** (Supplementary): Only when explicitly configured and available

---

## Traffic Light Definitions

- **ğŸŸ¢ GREEN**: Requirements substantially aligned, minimal adaptation needed
- **ğŸŸ¡ YELLOW**: Significant differences exist, harmonization strategy needed
- **ğŸ”´ RED**: Conflicting requirements, fundamental approach change required per region

---

## Escalation Scenarios

Escalate to regulatory expert when:
- Conflicting requirements across regions (RED traffic light)
- Significant cost impact from regional differences
- Novel device type with no clear precedent in any region
- Multi-market submission timing critical for business

---

## VALID Framework Compliance

- **Verified**: All comparisons cite specific regulation sources (FDA CFR, EU MDR Articles, MFDS ì˜ë£Œê¸°ê¸°ë²•)
- **Accurate**: Comparison data matches current regulatory state (2026-01)
- **Linked**: References to specific regulation sections included
- **Inspectable**: Decision logic transparent (comparison dimensions clearly defined)
- **Deliverable**: Output stored in `.aria/products/<product-name>/<date>/comparison.md`

---

## Common Comparison Topics (Examples)

### Clinical Evidence
- Pre-market clinical data requirements
- Clinical evaluation report standards
- Post-market clinical follow-up

### Quality System
- QMS certification requirements
- Design control processes
- Supplier management

### Post-Market Surveillance
- Adverse event reporting thresholds
- Periodic safety update requirements
- Field corrective actions

### Labeling
- IFU content requirements
- Symbol standards (ISO 15223)
- Language requirements

### Technical Documentation
- Design history file structure
- Risk management file
- Clinical evaluation documentation

---

## Version History

**v1.0.0** (2026-02-11):
- Initial implementation for Phase 4
- FDA, EU MDR, MFDS comparison framework
- Side-by-side matrix generation
- Strategic recommendations
- Context Simplifier integration
- Korean language output
- Traffic light system
- VALID framework compliance

---

**Knowledge Base Cutoff**: 2026-01
**Next Update**: Quarterly regulatory updates
